Semaglutide medication belongs to a class of glucagon-like peptide-1 (GLP-1) receptor agonists, a group of anti-diabetic medications that help regulate blood sugar. It was first approved by the U.S. Food and Drug Administration (FDA) on December 5, 2017 for the treatment of type 2 diabetes.
Later, it received additional FDA approval for chronic weight management, expanding its use to individuals with obesity or overweight. In India, both semaglutide injection India and semaglutide tablet India options are available under different semaglutide brand India names such as Rybelsus and Wegovy.

Semaglutide is used to improve blood sugar control in type 2 diabetes and aid in weight management in individuals with obesity or overweight.

Semaglutide is typically administered as a subcutaneous injection at a convenient time once a week, on the same day each week. The injection can be given in the abdomen, thigh, or upper arm. These medication pens come with clear instructions on how to load the needle, dial the dose, and administer the injection. After injecting, dispose of the needle safely in a sharps container. Regular monitoring and follow-up with your healthcare provider are important to assess your progress and make any necessary adjustments to your treatment plan.

Semaglutide may cause side effects, including but not limited to nausea, vomiting, diarrhea, decreased appetite, headache, injection site reactions, and, in rare cases, more serious effects such as pancreatitis, thyroid tumors, kidney problems, and hypoglycemia

Semaglutide has been shown to cause thyroid C-cell tumors in animal studies.  It may increase the risk of pancreatitis (inflammation of the pancreas). Combined with other antidiabetic medications, this medication may increase the risk of hypoglycemia (low blood sugar). This medication may increase the risk of gallbladder-related events, such as cholelithiasis (gallstones) and acute inflammation. Some GLP-1 RAs, including semaglutide, have been associated with an increased heart rate. 

Individuals with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should avoid its use. Prompt medical attention is advised for severe abdominal pain, neck swelling, difficulty swallowing, or signs of allergic reactions. Caution is required in individuals with renal impairment. Inform your healthcare provider if you experience palpitations or a rapid heart rate. Dosage adjustments may be necessary. Close monitoring and consultation with a healthcare provider are crucial to manage these risks effectively.

Discuss your medical history with your healthcare provider, especially if you have a history of pancreatitis, thyroid issues, kidney or liver problems, or gallbladder disease. Monitor your blood sugar levels regularly to avoid hypoglycemia, particularly when taking other antidiabetic medications. Adhere strictly to the prescribed dosage and injection schedule, and follow proper injection techniques to minimize risks. Its injections may cause skin reactions at the injection site. Rotate injection sites and follow proper injection techniques to minimize this risk. Report any unusual symptoms, such as abdominal pain or skin reactions, promptly to your healthcare provider. Pregnant and breastfeeding women should consult a doctor before taking this medication. Regularly assess your overall health and any potential changes while using semaglutide, and attend follow-up appointments as your healthcare provider recommends.

1. Novo Nordisk Inc, FDA Food and Drug Safety Administration [September 20, 2019] [Accessed date 18th August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
2. Novo Nordisk Limited, EMC,  [25 Jan 2023], [Accessed date 18th August 2023]https://www.medicines.org.uk/emc/product/11507/pil

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.